Nome Químico: Sodium 4-[[(4-fluorophenyl)methyl]carbamoyl]-1-methyl-2-[2-(5-methyl-1,3,4-oxadiazole-2-carboxamido)propan-2-yl]-6-oxo-1,6-dihydropyrimidin-5-olate (as per EP); Sodium 4-[(4-fluorobenzyl)carbamoyl]-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-dihydropyrimidin-5-olate (as per USP)
Sorrisos: CC(C)(C(N1C)=NC(C(NCC2=CC=C(F)C=C2)=O)=C(O)C1=O)NC(C3=NN=C(C)O3)=O.[Na]
Inchi: InChI=1S/C18H22ClN3O5S/c19-16-6-5-15(28-16)18(26)22-10-14(23)9-21-13-3-1-12(2-4-13)20-7-8-27-11-17(24)25/h1-6,14,20-21,23H,7-11H2,(H,22,26)(H,24,25)/t14-/m0/s1
Development and validation of stability indicating RP-HPLC assay method of raltegravir in tablet dosage forms
By Shirisha, V.; Sairaju, B.; Illendula, Santhosh; Dutt, K. Rajeswar
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(10), 668-692
Stability indicating reverse-phase high performance liquid chromatography method for the determination of raltegravir in bulk and pharmaceutical formulation
By Annapurna, Mukthinuthalapati Mathrusri; Teja, Gunnam Ravi; Hemchand, S.; Babu, R. Ravi Chandra
From International Journal of Green Pharmacy (2018), 12(1Suppl.), S177-S180
Development and validation of RP-HPLC method for determination of raltegravir and its impurities in bulk drug and dosage forms
By Balaji, M.; AppaRao, K. M. Ch.; Ramakrishna, K.; Srinivasarao, V.
From Pharma Science Monitor (2014), 5(3Suppl.1), 187-196, 10 pp.